Today, Zealand Pharma (NASDAQ OMX: ZEAL) (“Zealand”), announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly and Company (“Lilly”).
Under the agreement, Zealand will collaborate with Lilly in the design and development of potentially first-in-class peptide therapeutics for the treatment of Type 2 diabetes and obesity based on a novel approach discovered by Lilly. The companies will share in the funding, risk and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.
Help employers find you! Check out all the jobs and post your resume.
